Page last updated: 2024-09-05

avasimibe and Granulocytic Leukemia, Chronic

avasimibe has been researched along with Granulocytic Leukemia, Chronic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bandyopadhyay, S; Cheng, JX; Li, J; Oh, ST; Traer, E; Tyner, JW; Zhou, A	1

Other Studies

1 other study(ies) available for avasimibe and Granulocytic Leukemia, Chronic

Article	Year
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PloS one, 2017, Volume: 12, Issue:7 Topics: Acetamides; Acetates; Animals; Apoptosis; Cell Proliferation; Cholesterol; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Esterification; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; Mutation; Protein Kinase Inhibitors; Sulfonamides; Sulfonic Acids; Xenograft Model Antitumor Assays	2017

Article

Year

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.

PloS one, 2017, Volume: 12, Issue:7

Topics: Acetamides; Acetates; Animals; Apoptosis; Cell Proliferation; Cholesterol; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Esterification; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; Mutation; Protein Kinase Inhibitors; Sulfonamides; Sulfonic Acids; Xenograft Model Antitumor Assays

2017